Search

Daratumumab, a CD38 monoclonal antibody study in advanced multiple myeloma – an open-label, dose escalation followed by open-label extension in a single-arm phase I/II study

Daratumumab is a human CD38 monoclonal antibody being tested against multiple myeloma, but it could also have potential in a broad range of other hematological diseases.

Read more

Pivotal Ruxolitinib Data Shows Promise for Patients with PV.

 

Polycythemia vera (PV) is a chronic, incurable blood cancer with limited treatment options. If uncontrolled, PV can cause serious cardiovascular complications, such as stroke and heart attack.

Read more

Epidemiology of infection in AML: A European Hematology Association survey (EPIAMLINF)

Project team

Jon Salmanton-García
Institution: University of Cologne, Germany

Biography: My research focuses on infectious diseases in hematology, particularly fungal infections and viral complications in immunocompromised patients.

Read more

King Baudouin Foundation – Calls with a relevance to hematology

The King Baudouin Foundation is an actor for change and innovation, serving the public interest and increasing social cohesion. It endeavours to maximise its impact through capacity building among organisations and people who contribute to building a better society.

Read more

José Carreras Award handed out at the 17th Congress of EHA

He has made seminal contributions to myeloma cell biology. These included studies of the diagnostic and prognostic roles of immunophenotyping, morphology and molecular genetics together with investigation of disease evolution and the significance of minimal residual disease.

Read more

Training vital for new era of patient-centric healthcare

Christine Chomienne, president of the European Hematology Association (EHA), was speaking at the third annual conference of the European Alliance for Personalised Medicine (EAPM) – a Brussels-based organization that brings together stakeholders from academia, through research,…

Read more

Chairs and Members

Chair (re-appointment, 2023–2026)Josef Vormoor—Professor of Hematological Malignancies in Children, University Medical Center Utrecht (The Netherlands)

Co-chair (re-appointment, 2023–2026)Maria Ester Bernardo—Clinical Coordinator, Clinical Research Unit, San Raffaele Telethon Institute for Gene Therapy (Italy)

SWG Steering Committee members (2024–2027 term)
SWG Secretary—Francesco Saglio, AOU Città…

Read more

Do generics of imatinib jeopardize patient safety for the sake of saving money? An experience in Turkish patients.

 

The high cost of tyrosine kinase inhibitors developed for chronic myeloid leukemia is a major concern for the health care payers, especially in countries with restricted resources.

Read more